Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency

Journal of Renal Care

Volumn 35, Issue 4, 2009, Pages 211-218

  Yaganti, Vamsee ^a   Alani, Firas ^a   Yaganti, Sushmita ^b   Goldberg, Sheldon ^a   McCormick, Daniel ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Carotid artery angiography; Carotid artery stenosis; Carotid artery stenting; Contrast induced nephropathy; Gadolinium; Iodinated contrast

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; IOPAMIDOL;

AGED; ANGIOGRAPHY; ARTICLE; BLOOD; BRAIN ANGIOGRAPHY; CAROTID ARTERY OBSTRUCTION; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LENGTH OF STAY; MALE; METHODOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RADIOGRAPHY; RETROSPECTIVE STUDY; SAFETY; STATISTICS; STENT; STROKE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; CAROTID STENOSIS; CEREBRAL ANGIOGRAPHY; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; INCIDENCE; IOPAMIDOL; KIDNEY DISEASES; LENGTH OF STAY; MALE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SAFETY; STENTS; STROKE; TREATMENT OUTCOME;

EID: 71849115951     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2009.00120.x     Document Type: Article

References (26)

1. Ailawadi G., Stanley J.C., Williams D.M. et al. (2003). Gadolinium as a nonnephrotoxic contrast agent for catheter-based artériographie evaluation of renal arteries in patients with azotemia. J Vase Surg 37, 346-352.
2. Andrade L., Campos S.B. & Seguro A.C. (1998). Hypercholesterolemia aggravates radio contrast nephrotoxicity: protective role of L-arginine. Kidney Int 53, 1736-42.
3. Briguori C., Colombo A., Airoldi F. et al. (2006). Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67, 175-180.
4. Campbell D.R., Flemming B.K., Mason W.F. et al. (1990). A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol 41, 133-137.
5. Davidson C., Stacul F., McCullough P. et al. (2006). Contrast medium use. Am J Cardiol 98, 42K-58K.
6. Erley W.K., Zaetta J., Borders G.T. et al. (2000). Gadopentetate dimeg-lumine as a contrast agent in common carotid arteriography. Am J Neuroradiol 21, 964-967.
7. Erley C.M., Bader B.D., Berger E.D. et al. (2004). Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotemic patients. Nephrol Dial Transplant 19, 2526-2531.
8. Gomes A.S., Baker J.D., Martin-Paredero V. et al. (1985). Acute renal dysfunction after major autobiography. Am J Roentgenol 145, 1249-53.
9. Hammer F.D., Goffette P.P., Malaise J. et al. (1999). Gadolinium dimeg-lumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 9, 128-136.
10. Hammer F.D., Malaise J., Goffette P.P. et al. (2000). Gadolinium dimeg-lumine: an alternative contrast agent for digital subtraction angiography in patients with renal failure. Transplant Proc 32, 432-433.
11. lakovou I., Dangas G., Mehran R. et al. (2003). Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 1, 18-22.
12. Janus N., Launay-Vacher V., Karie S. et al. (2008). Prevalence of nephrogenic systemic fibrosis in renal insufficiency: results in FINEST study. Eur J Radiol, doi: 10.1016/j.ejrad.2008.11.021.
13. Lindsay J., Apple S., Pinnow E.E. et al. (2003). Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 59, 338-343.
14. Martin-Paredero V. Dixon S.M. & Baker J.D. (1983). Risk of renal failure after major angiography. Arch Surg 118, 1417-1420.
15. McCullough P.A., Wolyn R., Rocher L.L. et al. (1997). Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103, 368-375.
16. McCullough P., Adam A. & Becker C.R. et al. (2006a) Risk predication of contrast-induced nephropathy. Am J Cardiol 98, 27K-36K.
17. McCullough P.A. (2006b). Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 67, 335-343.
18. McCullough P.A., Bertrand M.E., Brinker J.A. et al. (2006c). A metaanalysis of renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48, 692-699.
19. Mehran R., Aymong E., Nikolsky E. et al. (2004). A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44, 1393-1399.
20. Nash K., Hafeez A. & Hou S. (2002). Hospital-acquired renal insufficiency. Am J Kidney Dis 39, 930-936.
21. Perazella M.A. & Rodby R.A. (2007). Gadolinium use in patients with kidney isease: a cause for concern. Semin Dial 20, 179-185.
22. Prince M.R., Arnoldus C. & Frisoli J.K. (1996). Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1, 162-166.
23. Rieger J., Sitter T., Toepfer M. et al. (2002). Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17, 824-828.
24. Sam A.D., Morasch M.D., Collins J. et al. (2003). Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vase Surg 38, 313-318.
25. Thomsen H.S. (2004). Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14, 1654-1656.
26. Townsend R.R., Cohen D.L., Katholi R. et al. (2000). Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 36, 1207-1212.